MA38949A1 - Forme saline d'hydrochlorure pour inhibition d'ezh2 - Google Patents

Forme saline d'hydrochlorure pour inhibition d'ezh2

Info

Publication number
MA38949A1
MA38949A1 MA38949A MA38949A MA38949A1 MA 38949 A1 MA38949 A1 MA 38949A1 MA 38949 A MA38949 A MA 38949A MA 38949 A MA38949 A MA 38949A MA 38949 A1 MA38949 A1 MA 38949A1
Authority
MA
Morocco
Prior art keywords
dgat1
ezh2
hydrochloride
inhibition
saline form
Prior art date
Application number
MA38949A
Other languages
English (en)
Inventor
Kevin W Kuntz
Hyeong-Wook Choi
Steven Mathieu
Kristen Sanders
Arani Chanda
Original Assignee
Eisai R&D Man Co Ltd
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Epizyme Inc filed Critical Eisai R&D Man Co Ltd
Publication of MA38949A1 publication Critical patent/MA38949A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés qui sont des inhibiteurs d'acyl-coenzyme a: diacylglycérol transférase 1 (dgat1), des compositions pharmaceutiques les contenant, des procédés pour leur préparation, ainsi que leur utilisation en thérapie, seuls ou en combinaison avec des thérapies de gestion du poids ou autre thérapie de diminution des triglycérides pour la prévention ou le traitement de maladies liées à un dysfonctionnement de dgat1 ou dans lesquelles une modulation de l'activité de dgat1 peut avoir un bénéfice thérapeutique.
MA38949A 2013-10-16 2014-10-15 Forme saline d'hydrochlorure pour inhibition d'ezh2 MA38949A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361891786P 2013-10-16 2013-10-16
PCT/US2014/060724 WO2015057859A1 (fr) 2013-10-16 2014-10-15 Forme saline d'hydrochlorure pour inhibition d'ezh2

Publications (1)

Publication Number Publication Date
MA38949A1 true MA38949A1 (fr) 2017-07-31

Family

ID=52828660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38949A MA38949A1 (fr) 2013-10-16 2014-10-15 Forme saline d'hydrochlorure pour inhibition d'ezh2

Country Status (24)

Country Link
US (3) US10040782B2 (fr)
EP (2) EP3057962B1 (fr)
JP (2) JP6608812B2 (fr)
KR (1) KR102142177B1 (fr)
CN (1) CN105829302B (fr)
AU (2) AU2014337300B2 (fr)
CA (1) CA2925889C (fr)
CL (1) CL2016000866A1 (fr)
DK (1) DK3057962T3 (fr)
EA (1) EA038869B1 (fr)
ES (1) ES2960953T3 (fr)
FI (1) FI3057962T3 (fr)
HU (1) HUE063984T2 (fr)
IL (1) IL244787B (fr)
LT (1) LT3057962T (fr)
MA (1) MA38949A1 (fr)
MX (1) MX2016004703A (fr)
MY (1) MY179802A (fr)
PE (1) PE20161273A1 (fr)
PL (1) PL3057962T3 (fr)
PT (1) PT3057962T (fr)
SG (2) SG11201602269QA (fr)
SI (1) SI3057962T1 (fr)
WO (1) WO2015057859A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9394283B2 (en) 2012-04-13 2016-07-19 Epizyme, Inc. Salt form of a human histone methyltransferase EZH2 inhibitor
CA2887243C (fr) 2012-10-15 2024-04-09 Epizyme, Inc. Methodes de traitement du cancer
KR102142177B1 (ko) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Ezh2 억제용 하이드로클로라이드 염 형태
CA2931263A1 (fr) 2013-12-06 2015-06-11 Epizyme, Inc. Polytherapie pour le traitement du cancer
IL285201B2 (en) 2014-06-17 2024-05-01 Epizyme Inc EZH2 inhibitors for the treatment of lymphoma
IL310279A (en) 2014-10-16 2024-03-01 Epizyme Inc Method for treating cancer
HUE062159T2 (hu) * 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
CN108135908A (zh) 2015-04-20 2018-06-08 Epizyme股份有限公司 用于治疗癌症的组合疗法
EP3307713A4 (fr) 2015-06-10 2019-01-23 Epizyme, Inc. Inhibiteurs d'ezh2 pour traiter le lymphome
KR20180042356A (ko) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
WO2017132518A1 (fr) 2016-01-29 2017-08-03 Epizyme, Inc. Polythérapie pour le traitement du cancer
WO2017210395A1 (fr) 2016-06-01 2017-12-07 Epizyme, Inc. Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3471830A4 (fr) 2016-06-17 2020-02-26 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
TW201831181A (zh) 2017-01-19 2018-09-01 日商第一三共股份有限公司 用以用於治療ｈｔｌｖ－１相關脊髓病之醫藥組成物
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
EP3630080A4 (fr) 2017-06-02 2021-03-10 Epizyme, Inc. Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
WO2019050924A1 (fr) 2017-09-05 2019-03-14 Epizyme, Inc. Polythérapie pour le traitement du cancer
EP3823671B1 (fr) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition de sous-unités de prc2 permettant de traiter des troubles oculaires
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
KR20220130698A (ko) * 2019-12-20 2022-09-27 에피자임, 인코포레이티드 Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물
EP4514391A1 (fr) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combinaison d'un conjugué anticorps-médicament avec un inhibiteur de l'ezh1 et/ou de l'ezh2

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
US5716993A (en) 1993-12-27 1998-02-10 Eisai Co., Ltd. Anthranilic acid derivatives
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
EP1117635A1 (fr) 1998-09-30 2001-07-25 The Procter & Gamble Company Cetoamides 2-substitues
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
KR100828982B1 (ko) 2000-12-28 2008-05-14 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
ATE447971T1 (de) 2002-02-19 2009-11-15 Shionogi & Co Antipruriginosa
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
EP1765994B1 (fr) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Complexe d'histone methyltransferase reconstitue et methodes associees d'identification de modulateurs
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7923219B2 (en) 2005-06-02 2011-04-12 The University Of North Carolina At Chapel Hill Ubiquitin E3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DK1940821T3 (da) 2005-10-19 2013-06-10 Gruenenthal Gmbh Nye vanilloid-receptorligander og deres anvendelse til fremstilling af lægemidler.
KR20080057296A (ko) 2005-10-21 2008-06-24 머크 앤드 캄파니 인코포레이티드 칼륨 채널 억제제
WO2007053480A2 (fr) 2005-10-28 2007-05-10 The University Of North Carolina At Chapel Hill Proteine demethylase a domaine jmjc
EP1966141A1 (fr) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Heterocycles a six elements utiles en tant qu inhibiteurs de serine protease
EP2730661A1 (fr) 2006-01-20 2014-05-14 The University of North Carolina at Chapel Hill Cibles diagnostiques et thérapeutiques pour la leucémie
KR20080110905A (ko) 2006-05-15 2008-12-19 아이알엠 엘엘씨 테레프탈라메이트 화합물 및 조성물, 및 ｈｉｖ 인테그라제억제제로서의 그들의 용도
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
EP2137158A4 (fr) 2007-02-28 2012-04-18 Methylgene Inc Inhibiteurs à petite molécule de protéines arginine méthyltransférases (prmt)
WO2008113006A1 (fr) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Procédés d'utilisation de composés à base de quinolinone dans le traitement des maladies ou des affections associées aux canaux sodiques
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (fr) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions et méthodes pour inhiber la protéine ezh2
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2009124137A2 (fr) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Procédé de suppression d’une transcription de gène par méthylation d’histone lysine
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US8299093B2 (en) 2008-08-08 2012-10-30 New York Blood Center, Inc. Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
JP2012522013A (ja) 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
WO2011011366A2 (fr) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents pour stimuler l'activité d'enzymes de modification par méthyle et procédés d'utilisation de ceux-ci
CA2784899A1 (fr) 2009-12-30 2011-07-07 Avon Products, Inc. Composition eclaircissante topique et utilisations de celle-ci
EA023788B1 (ru) 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
WO2012005805A1 (fr) 2010-05-07 2012-01-12 Glaxosmithkline Llc Aza-indazoles
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インダゾール
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (fr) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012118812A2 (fr) 2011-02-28 2012-09-07 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
RU2704445C2 (ru) 2012-03-12 2019-10-28 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
US9394283B2 (en) 2012-04-13 2016-07-19 Epizyme, Inc. Salt form of a human histone methyltransferase EZH2 inhibitor
SG10201608579UA (en) 2012-04-13 2016-12-29 Epizyme Inc Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2887243C (fr) 2012-10-15 2024-04-09 Epizyme, Inc. Methodes de traitement du cancer
PE20150887A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
WO2014100646A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Composés 1,4-pyridones
CA2894222A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Composes heteroaryles bicycliques 1,4-pyridone
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CA2903572A1 (fr) 2013-03-15 2014-10-23 Epizyme, Inc. Composes de benzene substitues
WO2015010049A1 (fr) 2013-07-19 2015-01-22 Epizyme, Inc. Composés de benzène substitués
EP3022195A2 (fr) 2013-07-19 2016-05-25 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
KR102142177B1 (ko) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Ezh2 억제용 하이드로클로라이드 염 형태

Also Published As

Publication number Publication date
US20180282312A1 (en) 2018-10-04
EP4324525A3 (fr) 2024-07-17
NZ718201A (en) 2021-09-24
JP6608812B2 (ja) 2019-11-20
LT3057962T (lt) 2023-12-11
PL3057962T3 (pl) 2024-01-29
FI3057962T3 (fi) 2023-11-03
PT3057962T (pt) 2023-11-07
HUE063984T2 (hu) 2024-02-28
MY179802A (en) 2020-11-16
CA2925889C (fr) 2020-09-29
EP3057962A1 (fr) 2016-08-24
ES2960953T3 (es) 2024-03-07
KR20160082993A (ko) 2016-07-11
EP4324525A2 (fr) 2024-02-21
JP2019052181A (ja) 2019-04-04
SG11201602269QA (en) 2016-04-28
AU2014337300A1 (en) 2016-04-14
AU2019202246A1 (en) 2019-04-18
US20210017163A1 (en) 2021-01-21
PE20161273A1 (es) 2016-12-18
US20160237068A1 (en) 2016-08-18
CA2925889A1 (fr) 2015-04-23
IL244787A0 (en) 2016-04-21
DK3057962T3 (da) 2023-11-06
US10710987B2 (en) 2020-07-14
IL244787B (en) 2022-04-01
SI3057962T1 (sl) 2024-01-31
CL2016000866A1 (es) 2016-12-23
US10040782B2 (en) 2018-08-07
CN105829302B (zh) 2020-09-08
EP3057962B1 (fr) 2023-10-18
WO2015057859A1 (fr) 2015-04-23
AU2014337300B2 (en) 2019-01-03
CN105829302A (zh) 2016-08-03
KR102142177B1 (ko) 2020-08-07
JP2016533349A (ja) 2016-10-27
EP3057962A4 (fr) 2017-05-24
EA201690650A1 (ru) 2016-10-31
EA038869B1 (ru) 2021-10-29
MX2016004703A (es) 2017-02-28
SG10201901977XA (en) 2019-04-29

Similar Documents

Publication Publication Date Title
MA38949A1 (fr) Forme saline d'hydrochlorure pour inhibition d'ezh2
MA49055B1 (fr) Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf
MA39753B1 (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA45985A (fr) Inhibiteurs de diacylglycérol acyltransférase 2
MA40290A1 (fr) Agents immunorégulateurs
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
GEAP202315297A (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
PH12014500239A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
PH12014500371A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA38102A1 (fr) Nouveaux composés utilisés comme inhibiteurs de diacylglycérol acyltransférase
UA115079C2 (uk) Сполуки як інгібітори діацилгліцеринацилтрансферази
FR3038605B1 (fr) Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
MA45990B1 (fr) Combinaison d'agonistes inverses du récepteur de l'histamine-3 avec des inhibiteurs de l'acétylcholinestérase
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales
EP2101809A4 (fr) Composition pharmaceutique contenant de l'arazyme et destinée à prévenir des troubles hépatiques
MA38206A1 (fr) Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées